Chronic fatigue syndrome and subsequent risk of cancer among elderly US adults
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The cause of chronic fatigue syndrome (CFS) is unknown but is thought to be associated with immune abnormalities or infection. Because cancer can arise from similar conditions, associations between CFS and cancer were examined in a population‐based case‐control study among the US elderly. METHODS: Using linked Surveillance, Epidemiology, and End Results (SEER)‐Medicare registry data, approximately 1.2 million cancer cases and 100,000 controls (age range, 66‐99 years; 1992‐2005) were evaluated. CFS was identified in the period more than 1 year prior to selection, using linked Medicare claims. Unconditional logistic regression was used to estimate the odds ratios (ORs) comparing the CFS prevalence in cases and controls, adjusting for age, sex, and selection year. All statistical tests were 2‐sided. RESULTS: CFS was present in 0.5% of cancer cases overall and 0.5% of controls. CFS was associated with an increased risk of non‐Hodgkin lymphoma (NHL) (OR = 1.29, 95% confidence interval [CI] = 1.16‐1.43, P = 1.7 × 10−6). Among NHL subtypes, CFS was associated with diffuse large B cell lymphoma (OR = 1.34, 95% CI = 1.12‐1.61), marginal zone lymphoma (OR = 1.88, 95% CI = 1.38‐2.57), and B cell NHL not otherwise specified (OR = 1.51, 95% CI = 1.03‐2.23). CFS associations with NHL overall and NHL subtypes remained elevated after excluding patients with medical conditions related to CFS or NHL, such as autoimmune conditions. CFS was also associated, although not after multiple comparison adjustment, with cancers of the pancreas (OR = 1.25, 95% CI = 1.07‐1.47), kidney (OR = 1.27, 95% CI = 1.07‐1.49), breast (OR = 0.85, 95% CI = 0.74‐0.98), and oral cavity and pharynx (OR = 0.70, 95% CI = 0.49‐1.00). CONCLUSIONS: Chronic immune activation or an infection associated with CFS may play a role in explaining the increased risk of NHL. Cancer 2012. © 2012 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Urisman, A., Molinaro, R. J., Fischer, N., Plummer, S. J., Casey, G., Klein, E. A., Malathi, K., Magi-Galluzzi, C., Tubbs, R. R., Ganem, D., et al. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020025 · Cited by 577 · cited 1×
“In other studies, XMRVDNA and protein expression have been detected in prostate tumor tissues.(13,14) The possible role of XMRV might suggest that patients with CFS would have an elevated risk of prostate cancer.”
BackgroundRetractedLombardi, V. C., Ruscetti, F. W., Das Gupta, J., Pfost, M. A., Hagen, K. S., Peterson, D. L., Ruscetti, S. K., Bagni, R. K., Petrow-Sadowski, C., Gold, B., et al. (2009) · Science · doi:10.1126/science.1179052 · Cited by 538 · cited 1×
“patients with CFS, compared with 4% of healthy controls.(12) In other studies, XMRVDNA and protein expression have been detected in prostate tumor tissues.”
ResultRetractedPrins, J. B., van der Meer, J. W., & Bleijenberg, G. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68073-2 · Cited by 974
A community-based study of chronic fatigue syndrome.
Jason, L. A., Richman, J. A., Rademaker, A. W., Jordan, K. M., Plioplys, A. V., Taylor, R. R., McCready, W., Huang, C.-F., & Plioplys, S. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.18.2129 · Cited by 811 · cited 4×
“4% in 2 population-based surveys in Chicago, Illinois (n 1⁄4 18,668), and Wichita, Kansas (n 1⁄4 7162).(7,8) In the 2 studies, the median duration of CFS symptoms was between 2.”
BackgroundInfluentialMorton, L. M., Turner, J. J., Cerhan, J. R., Linet, M. S., Treseler, P. A., Clarke, C. A., Jack, A., Cozen, W., Maynadié, M., Spinelli, J. J., et al. (2007) · Blood · doi:10.1182/blood-2006-11-051672 · Cited by 387 · cited 1×
“NHL was classified based on the World Health Organization scheme and included chronic lymphocytic leukemia.(22) Controls (N 1⁄4 100,000) were selected from the 5% random sample of Medicare beneficiaries living in SEER areas and were frequency-matched to cases by sex, age category (66-69, 70-74, 75-79, 80-84, and 85-99…”
MethodRecombinant Origin of the Retrovirus XMRV
Paprotka, T., Delviks-Frankenberry, K. A., Cingöz, O., Martinez, A., Kung, H.-J., Tepper, C. G., Hu, W.-S., Fivash, M. J., Coffin, J. M., & Pathak, V. K. (2011) · Science · doi:10.1126/science.1205292 · Cited by 240
Cited by
Cytokine signature associated with disease severity in chronic fatigue syndrome patients
Montoya, J. G., Holmes, T. H., Anderson, J. N., Maecker, H. T., Rosenberg-Hasson, Y., Valencia, I. J., Chu, L., Younger, J. W., Tato, C. M., & Davis, M. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710519114 · Cited by 402
Distinct plasma immune signatures in ME/CFS are present early in the course of illness
Hornig, M., Montoya, J. G., Klimas, N. G., Levine, S., Felsenstein, D., Bateman, L., Peterson, D. L., Gottschalk, C. G., Schultz, A. F., Che, X., et al. (2015) · Science Advances · doi:10.1126/sciadv.1400121 · Cited by 263
Deficient EBV-specific B- and T-cell response in patients with chronic fatigue syndrome
Loebel, M., Strohschein, K., Giannini, C., Koelsch, U., Bauer, S., Doebis, C., Thomas, S., Unterwalder, N., von Baehr, V., Reinke, P., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085387 · Cited by 86
“Abnormal expression of both viral lytic genes and impaired EBV-specific T-cell responses were demonstrated in SLE patients [80], [81].”
Bradley, A. S., Ford, B., & Bansal, A. S. (2013) · Clinical and Experimental Immunology · doi:10.1111/cei.12043 · Cited by 73
Mensah, F., Bansal, A., Berkovitz, S., Sharma, A., Reddy, V, Leandro, M. J., & Cambridge, G. (2016) · Clinical and Experimental Immunology · doi:10.1111/cei.12749 · Cited by 34
Metadata
- Authors
- Chang, C. M., Warren, J. L., & Engels, E. A.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2012-05-30
- Volume
- 118
- Issue
- 23
- Pages
- 5929-5936
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1987094938
- Cited by
- 58
- References
- 6
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.